


**Enterprise P&T Meeting
Committee Meeting Minutes
Email Proxy Vote March 5, 2020**

Committee Member	Approved	Reject	Excused	Committee Member	Approved	Reject	Excused
Christopher Antypas, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Emily Kryger, PharmD*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
David Batluck, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Kelly Martin, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Donald Beam, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Susan McAllister, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Floyd (John) Brinley, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Kendra Michael, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
William Burnham, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Betty Muller, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cathryn Caton, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Michelle Murphy, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Kirton Caton, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Lavdena Orr, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Don Cooper, RPh	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Eric Peters, PharmD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Tracey Davis, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Andrew Peterson, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rogers Elebra, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	David Petkash, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Fury Fecondo, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Kirby Smith, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Gus Geraci, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Wayne Weart, PharmD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Lily Higgins, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rani Whitfield, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Robert Hockmuth, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rodney Wise, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Karen Jordan, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Rejection of Adakveo PA criteria

Item	Recommendations	Vote Results	Action/ Person Responsible
<p>Criteria Recommendation: Plan specific coverage and prior authorization criteria update for Oxbryta</p>	<ol style="list-style-type: none"> 1. PerformRx recommends approving the attached prior authorization criteria for the applicable lines of business. 2. Formulary status change recommended by LOB: <ol style="list-style-type: none"> a. KF/AHC/AHNE/ [REDACTED] – add Oxbryta to Tier 4 with PA 	<p>Total Sent – 29 Total Responses – 19 Approved – 19 Rejected – 0 Excused – 10</p> <p>End: 03/16/2020</p>	<p>PerformRx will implement the criteria per the outcome of the committee vote.</p> <p>The vote has been approved with 19 approvals and no rejections received.</p>
<p>Criteria Recommendation: Plan specific coverage and prior authorization criteria update for Adakveo</p>	<ol style="list-style-type: none"> 1. PerformRx recommends approving the attached prior authorization criteria for the applicable lines of business. 2. Formulary status change recommended by LOB: <ol style="list-style-type: none"> a. KF/AHC/AHNE/ [REDACTED] – add Adakveo to Tier 4 with PA 	<p>Total Sent – 29 Total Responses – 19 Approved – 18 Rejected – 1 Excused – 10</p> <p>End: 03/16/2020</p>	<p>PerformRx will implement the criteria per the outcome of the committee vote.</p> <p>The vote has been approved with 18 approvals and 1 rejection received. The rejection was based on the PA criteria requirement of 2 or more pain crises in the last 12 months instead of 1.</p>
<p>Formulary Addition: Melatonin</p>	<ol style="list-style-type: none"> 1. Add all single agent melatonin products to T3 supplemental formulary for Pennsylvania. 	<p>Total Sent – 29 Total Responses – 19 Approved – 19 Rejected – 0</p>	<p>PerformRx will implement the criteria per the outcome of the committee vote.</p>

		Excused – 10 End: 03/16/2020	The vote has been approved with 19 approvals and no rejections received.
--	--	---------------------------------	--



William Burnham, MD, FAAFP, CPE - Chair

3/17/2020

Date